Report from a Consensus Conference on the treatment of M énière's disease with betahistine: rationale, methodology and results.

Report from a Consensus Conference on the treatment of Ménière's disease with betahistine: rationale, methodology and results. Acta Otorhinolaryngol Ital. 2018 Oct;38(5):460-467 Authors: Casani AP, Guidetti G, Schoenhuber R, Consensus Conference Group Abstract Ménière's disease is a disorder of the inner ear that causes vertigo, tinnitus, fullness and hearing loss. Although several treatments are available, the success rate is reported to be around 70%, similar to placebo. Betahistine, a weak H1 receptor agonist and an effective H3 receptor antagonist, is frequently prescribed for Ménière's disease, especially to reduce recurrent vertigo attacks. The effects of this drug on hearing and other audiological symptoms remains unclear. Given the inconclusive reports in...

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2Ry3KbO